LAVA Therapeutics NV
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more
LAVA Therapeutics NV (LVTX) - Net Assets
Latest net assets as of September 2025: $12.68 Million USD
Based on the latest financial reports, LAVA Therapeutics NV (LVTX) has net assets worth $12.68 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($51.91 Million) and total liabilities ($39.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.68 Million |
| % of Total Assets | 24.43% |
| Annual Growth Rate | 36.53% |
| 5-Year Change | 264.06% |
| 10-Year Change | N/A |
| Growth Volatility | 590.21 |
LAVA Therapeutics NV - Net Assets Trend (2019–2024)
This chart illustrates how LAVA Therapeutics NV's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LAVA Therapeutics NV (2019–2024)
The table below shows the annual net assets of LAVA Therapeutics NV from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $27.75 Million | -45.79% |
| 2023-12-31 | $51.18 Million | -40.52% |
| 2022-12-31 | $86.04 Million | -27.31% |
| 2021-12-31 | $118.37 Million | +1453.17% |
| 2020-12-31 | $7.62 Million | +30.41% |
| 2019-12-31 | $5.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LAVA Therapeutics NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16126900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.72 Million | 13.40% |
| Other Comprehensive Income | $-12.65 Million | -45.61% |
| Other Components | $211.66 Million | 762.86% |
| Total Equity | $27.75 Million | 100.00% |
LAVA Therapeutics NV Competitors by Market Cap
The table below lists competitors of LAVA Therapeutics NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Amot Investments Ltd
TA:AMOT
|
$30.57 Million |
|
Ledesma SAAI
BA:LEDE
|
$30.58 Million |
|
M2N Co.Ltd
KQ:033310
|
$30.58 Million |
|
Emperor Capital Group Limited
F:HQF
|
$30.59 Million |
|
Rompetrol Well
RO:PTR
|
$30.56 Million |
|
TY Holdings Co Ltd
KO:363280
|
$30.56 Million |
|
Para Light Electronics Co Ltd
TW:6226
|
$30.55 Million |
|
Very Good Tour Co. Ltd
KQ:094850
|
$30.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LAVA Therapeutics NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 51,178,000 to 27,745,000, a change of -23,433,000 (-45.8%).
- Net loss of 25,114,000 reduced equity.
- Other comprehensive income decreased equity by 1,756,000.
- Other factors increased equity by 3,437,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.11 Million | -90.52% |
| Other Comprehensive Income | $-1.76 Million | -6.33% |
| Other Changes | $3.44 Million | +12.39% |
| Total Change | $- | -45.79% |
Book Value vs Market Value Analysis
This analysis compares LAVA Therapeutics NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.68x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.48x to 1.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.32 | $1.74 | x |
| 2020-12-31 | $0.30 | $1.74 | x |
| 2021-12-31 | $5.99 | $1.74 | x |
| 2022-12-31 | $3.32 | $1.74 | x |
| 2023-12-31 | $1.91 | $1.74 | x |
| 2024-12-31 | $1.03 | $1.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LAVA Therapeutics NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -90.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -209.60%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 2.91x
- Recent ROE (-90.52%) is above the historical average (-103.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -165.76% | 0.00% | 0.00x | 1.51x | $-10.27 Million |
| 2020 | -208.99% | -425.06% | 0.18x | 2.69x | $-16.69 Million |
| 2021 | -38.31% | -906.94% | 0.04x | 1.18x | $-57.18 Million |
| 2022 | -37.08% | -164.55% | 0.14x | 1.67x | $-40.51 Million |
| 2023 | -81.81% | -618.57% | 0.07x | 1.99x | $-46.99 Million |
| 2024 | -90.52% | -209.60% | 0.15x | 2.91x | $-27.89 Million |
Industry Comparison
This section compares LAVA Therapeutics NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LAVA Therapeutics NV (LVTX) | $12.68 Million | -165.76% | 3.09x | $30.56 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |